1HM.F Adaptive Biotechnologies Corporation
- Market cap
- EUR 4.20B
- P/E
- -
- P/B
- 25.14x
- ROE
- -43.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 1HM.F undervalued?
Graham numberThe Graham number of Adaptive Biotechnologies Corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Adaptive Biotechnologies Corporation fundamental analysis
No fundamental analysis for Adaptive Biotechnologies Corporation yet.
Adaptive Biotechnologies Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are …
Full company profileAdaptive Biotechnologies Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Adaptive Biotechnologies Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 38.4M | 55.7M | 85.1M | 98.4M | 154M | 185M | 170M | 179M | 277M | 302M |
| Gross Profit | 22.8M | 36.0M | 62.8M | 75.9M | 105M | 127M | 94.7M | 107M | 206M | 223M |
| Operating Income | -43.6M | -49.8M | -78.4M | -153M | -209M | -200M | -202M | -155M | -57.1M | -47.2M |
| EBITDA | -37.8M | -43.8M | -70.6M | -144M | -195M | -194M | -189M | -129M | -29.8M | -53.2M |
| Net Income | -42.8M | -46.4M | -68.6M | -146M | -207M | -200M | -225M | -159M | -59.5M | -75.9M |
| EPS | -0.35 | -0.38 | -0.55 | -1.06 | -1.47 | -1.40 | -1.56 | -1.08 | -0.39 | -0.47 |
| Balance Sheet | ||||||||||
| Total Assets | 362M | 333M | 912M | 1.12B | 923M | 857M | 661M | 539M | 513M | 683M |
| Total Liabilities | 587M | 591M | 341M | 373M | 319M | 393M | 353M | 337M | 288M | 499M |
| Shareholders' Equity | -225M | -258M | 571M | 743M | 604M | 464M | 308M | 203M | 219M | 176M |
| Cash & Short-term Investments | 85.3M | 55.0M | 96.6M | 123M | 139M | 90.0M | 65.1M | 47.9M | 70.5M | 75.6M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -34.9M | -32.3M | 205M | -150M | -193M | -184M | -159M | -95.2M | -46.0M | -8.44M |
| Capital Expenditure | 2.42M | 6.30M | 11.2M | 18.8M | 61.7M | 16.3M | 11.9M | 3.66M | 2.96M | 5.21M |
| Free Cash Flow | -37.4M | -38.6M | 194M | -168M | -254M | -200M | -171M | -98.9M | -48.9M | -13.7M |
| Ratios | ||||||||||
| ROE | - | - | -12.0% | -19.7% | -34.3% | -43.1% | -73.0% | -78.7% | -27.2% | -43.1% |
| ROA | -11.8% | -14.0% | -7.5% | -13.1% | -22.4% | -23.4% | -34.1% | -29.6% | -11.6% | -11.1% |
| Net Profit Margin | -111.4% | -83.4% | -80.6% | -148.6% | -134.3% | -108.0% | -132.3% | -89.1% | -21.5% | -25.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Adaptive Biotechnologies Corporation dividends
Adaptive Biotechnologies Corporation has not paid dividends in the last 9 fiscal years.
Last stock split: 1:4 on Jul 15, 2026.
Who owns Adaptive Biotechnologies Corporation
- Insiders 1.27%
- Institutions 98.73%
- Public & others 0.00%
- Shares outstanding 162M
- Free float 128M
Adaptive Biotechnologies Corporation company profile
- Company name
- Adaptive Biotechnologies Corporation
- Ticker
- 1HM.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 624
- Fiscal year end
- December
- Address
- 1165 Eastlake Avenue East, Seattle, WA, United States, 98109
- Phone
- 206 659 0067
- Website
- adaptivebiotech.com
About Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Adaptive Biotechnologies Corporation management
10- Mr. Chad M. Robins M.B.A.Co-Founder, CEO & Chairman · born 1975
- Ms. Julie RubinsteinPresident & COO · born 1972
- Mr. Kyle PiskelVP, CFO & Principal Accounting Officer · born 1984
- Ms. Susan BobulskyChief Commercial Officer of MRD · born 1981
- Mr. Christopher Carlson Ph.D.Founder
- Ms. Karina CalzadillaVP of Investor Relations and FP&A
- Ms. Clarice McCauleyHead of Legal, Corporate Secretary, VP & Chief Compliance Officer
- Mr. Francis T. LoChief People Officer · born 1981
- Dr. Sharon Benzeno Ph.D.Chief Commercial Officer of Immune Medicine · born 1974
- Ms. Mary Pat LancelottaSenior Vice President, Global Market & Business Development